Akari Therapeutics (AKTX) Competitors $1.11 -0.02 (-1.74%) As of 07/14/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. VTYX, LXEO, THTX, BDTX, ALTS, LYEL, IKT, SKYE, GALT, and GLSIShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), Lyell Immunopharma (LYEL), Inhibikase Therapeutics (IKT), Skye Bioscience (SKYE), Galectin Therapeutics (GALT), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Ventyx Biosciences Lexeo Therapeutics Theratechnologies Black Diamond Therapeutics ALT5 Sigma Lyell Immunopharma Inhibikase Therapeutics Skye Bioscience Galectin Therapeutics Greenwich LifeSciences Akari Therapeutics (NASDAQ:AKTX) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Do institutionals and insiders hold more shares of AKTX or VTYX? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 38.1% of Akari Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Ventyx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, AKTX or VTYX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$19.79MN/AN/AVentyx BiosciencesN/AN/A-$135.12M-$1.75-1.61 Do analysts recommend AKTX or VTYX? Ventyx Biosciences has a consensus target price of $10.00, suggesting a potential upside of 255.87%. Given Ventyx Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Ventyx Biosciences is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility & risk, AKTX or VTYX? Akari Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Does the media prefer AKTX or VTYX? In the previous week, Akari Therapeutics and Akari Therapeutics both had 2 articles in the media. Ventyx Biosciences' average media sentiment score of 1.30 beat Akari Therapeutics' score of 0.38 indicating that Ventyx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ventyx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AKTX or VTYX more profitable? Ventyx Biosciences' return on equity of -47.45% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A -213.59% -65.60% Ventyx Biosciences N/A -47.45%-43.49% SummaryVentyx Biosciences beats Akari Therapeutics on 8 of the 10 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.75M$2.95B$5.54B$9.14BDividend YieldN/A2.43%5.01%4.00%P/E RatioN/A21.1628.6919.45Price / SalesN/A184.72373.1779.78Price / CashN/A41.0524.7227.47Price / Book1.327.758.255.58Net Income-$19.79M-$55.05M$3.19B$252.81M7 Day Performance-0.80%9.69%3.53%2.11%1 Month Performance-6.64%13.80%9.56%11.87%1 Year Performance-70.29%3.55%30.54%16.61% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics0.8729 of 5 stars$1.11-1.7%N/A-68.3%$35.75MN/A0.009VTYXVentyx Biosciences3.518 of 5 stars$2.04-1.9%$10.00+390.2%+9.8%$148.01MN/A-1.1730LXEOLexeo Therapeutics2.3583 of 5 stars$4.54+2.0%$16.60+265.6%-74.8%$147.73M$650K-1.3858Gap UpHigh Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+119.5%$147.14M$85.87M-39.63140Earnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.9017 of 5 stars$2.50-3.1%$12.80+412.0%-48.0%$146.71MN/A41.6790News CoveragePositive NewsALTSALT5 Sigma0.1383 of 5 stars$7.54-8.4%N/AN/A$143.65M$12.53M0.00170LYELLyell Immunopharma3.5142 of 5 stars$9.15-5.6%$15.00+63.9%-71.7%$143.49M$60K-0.37270IKTInhibikase Therapeutics1.2273 of 5 stars$1.93+2.1%$6.50+236.8%+33.3%$143.48MN/A-0.726SKYESkye Bioscience2.1682 of 5 stars$4.39-4.8%$16.60+278.1%-39.0%$142.80MN/A-5.3511GALTGalectin Therapeutics2.2764 of 5 stars$2.15-1.4%$6.00+179.1%+27.2%$137.98MN/A-2.999GLSIGreenwich LifeSciences2.1756 of 5 stars$10.07+0.4%$39.00+287.3%-30.8%$134.08MN/A-7.993 Related Companies and Tools Related Companies Ventyx Biosciences Competitors Lexeo Therapeutics Competitors Theratechnologies Competitors Black Diamond Therapeutics Competitors ALT5 Sigma Competitors Lyell Immunopharma Competitors Inhibikase Therapeutics Competitors Skye Bioscience Competitors Galectin Therapeutics Competitors Greenwich LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
